Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis.

Kaidireyahan WumaierWenqian LiNaifei ChenJiu-Wei Cui

Published in: Thrombosis journal (2021)

As compared to LMWHs, DOACs can be a cost-saving anticoagulant choice for the treatment of CAT in the general oncology population and gastrointestinal malignancy population.

Keyphrases

direct oral anticoagulants
venous thromboembolism
atrial fibrillation
palliative care
pulmonary embolism
combination therapy
smoking cessation
data analysis